Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes

Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Caicun Zhou, Tao Jiang

Abstract

Immune checkpoint inhibitors (ICIs) that target programmed cell death protein 1 (PD-1) and its ligand (PD-L1), or cytotoxic T lymphocyte antigen-4 (CTLA-4) elicit durable antitumor responses in multiple cancer types. Yet, only a minority of patients could derive clinical benefit (1).

Article Options

Download Citation